We develop novel therapies for hard-to-treat resistant cancers by targeting Mitochondrial Carriers


A drug discovery company utilizing its generated knowledge and know-how in the field for potentially targeting each of the 53 human Mitochondrial Carriers


We use our cloud-based computational chemistry platform and MITOLINE™ algorithm to model, predict and discover small molecules that target Mitochondrial Carriers

Unlocking Mitochondrial Carriers
to treat resistant cancers

The mitochondrial anion carriers are transport proteins that translocate specific metabolites necessary for cell viability across the impermeable inner mitochondrial membrane. In humans, mitochondrial carriers (SLC25A) are the largest solute carrier family, playing significant roles in various pathologies such as cancer and rare mitochondrial diseases. Consisting of 53 members (out of ~450 total SLC members), transporters of this family are extensively shown to be involved in different types of malignancies such as cervical, prostate, hepatocellular carcinoma, and breast cancer, among others.

However, despite being directly linked with severe pathologies, the number of drug discovery projects in the field is still very low, and Computer Aided Drug Design (CADD) campaigns are scarce due to the limited amount of solved 3D structures (i.e., solved 3D structures are only available for the non-H. sapiens ADP/ATP carrier). To discover new potential drugs targeting human mitochondrial carriers, MitoCareX Bio has developed its MITOLINE™ algorithm and other advanced computational capabilities to generate reliable 3D models for its mitochondrial proteins of interest – a major key step for utilizing CADD. To recognize novel small molecule scaffolds interacting with our proteins of interest, we use our advanced cloud-based computational platform to efficiently screen numerous small molecules against our 3D models. Our selected hit candidates are then progressed along the pre-clinical path.

Read more

Our Science

In Silico

Utilizing our MITOLINE™ algorithm, we characterize and model the substrate’s translocation pathway of mitochondrial carriers as a functional targeting site for our virtual screening campaigns.


We bioinformatically analyze multiple patients’ databases to recognize tumor-specific genetic fingerprints related to mitochondrial carriers. Understanding the involvement of a mitochondrial carrier of interest in clinically relevant settings is critical to our oncology drug development process.


To validate and monitor the activity of our virtual hit molecules, we tailor cell-based and cell-free bioassays with specific readouts.


Target SLC25A transporter
Area of focus
Exploratory icon
Discovery icon
Pre-clinical icon

MitoCareX Bio was founded in 2022 with the goal to utilize its computational chemistry knowledge and know how in the field of Mitochondrial Carriers in order to develop new transformative medicines

Partner with us


Our algorithm for the generation of reliable 3D comparative models of mitochondrial carriers

A major challenge for drug discovery in the field is the lack of solved H. sapiens 3D structures of mitochondrial carrier proteins (e.g., crystal structures, cryo-EM structures). While this lack of solved 3D structures may result in non-reliable 3D homology models, we have developed our MITOLINE™ algorithm to translate our knowledge concerning key amino acid sequences and specific residues within them. Using MITOLINE™ – the generation of reliable 3D comparative models is possible for our target mitochondrial carriers of interest.

Contact Us
Read more

Contact us

    Our investors


    A specialty pharmaceutical company